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Abstract
Hyperactivity of hypothalamic-pituitary mediated hormone responses, such as to stimulation with
a serotonin 1A (5-HT1A) receptor agonist, are a feature of depression which are normalized with
clinical improvement during drug therapy. We previously reported that SSRIs induce
desensitization of 5-HT1A receptor signaling in the paraventricular nucleus of the hypothalamus
(PVN) while estradiol benzoate (EB) produces a more rapid, partial desensitization. In the current
study, time-course and dose-response experiments demonstrated that two once daily doses of EB
is the minimum needed to induce the desensitization response as indicated by 5-HT1A receptor-
stimulated release of oxytocin and that 10 μg/kg/day EB produces the maximal response, a partial
desensitization of approximately 40%. The effects of two once daily injections of 10 μg/kg/day
EB on Gαz and RGSZ1 proteins were examined as components of the 5-HT1A receptor signaling
system, which mediates the release of oxytocin and adrenocorticotropin hormone. RGSZ1 appears
to be a major target for EB-mediated responses in the 5-HT1A receptor signaling system. A 55 kD
membrane-associate RGSZ1 protein was greatly increased in the PVN and rest of the
hypothalamus and moderately increased in the dorsal hippocampus and amygdala after EB
treatment as well as after an acute dose of a 5-HT1A receptor agonist. These results suggest that
EB is a candidate for adjuvant therapy with SSRIs to hasten the therapeutic response and that
RGSZ1 is a major target of EB therapy which could be explored as a target for novel therapeutic
approaches for the treatment of depression.
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1. INTRODUCTION
Recent clinical and preclinical evidence highlights the role of reproductive hormones in
mood disorders in women. Indeed, women are more likely than men to experience
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depression by nearly 2 to 1 (Silva et al., 2010). In women, depression is associated with
periods of hormone fluctuations such as during premenstrual and post-partum periods.
Furthermore, women have increased risk for depression during transition periods in their
reproductive cycle such peri-menopausal and early menopausal periods (Bromberger et al.,
2011; Cohen et al., 2006; Soares, 2010).
One of the major shortcomings of current therapies for depression is the extensive delay in
the clinical response; it takes weeks rather than hours or days for a therapeutic response as
with most medications. It is paramount to develop approaches that shorten the delay in the
clinical response. Estradiol is an effective treatment for depression in peri-menopausal
women (Rasgon et al., 2002; Schmidt et al., 2000; Soares et al., 2001). Furthermore,
estrogen may improve the clinical response to selective serotonin reuptake inhibitor (SSRI)
therapy (Rasgon et al., 2002; Schneider et al., 2001; Schneider et al., 1997). In a 6 week
clinical trial, fluoxetine significantly improved depressive symptoms in older women taking
estrogen replacement therapy (ERT) compared to women without ERT (Schneider et al.,
1997). In contrast, a 12 week trial of sertraline in older women with and without ERT
demonstrated only a small increase in response to depression with ERT (Schneider et al.,
2001). In a separate trial examining the effects of sertraline and ERT in depressed post-
menopausal women, ERT did not alter the improvement in depressive symptoms at the end
of the 12 week trial but did accelerate the anti-depressive responses at 2, 3 and 4 weeks of
treatment (Rasgon et al., 2007). Similar to the findings in the study by Rasgon and
colleagues (Rasgon et al., 2007), we and others have found an accelerated response to SSRIs
with estradiol treatment in a pre-clinical studies. Estradiol alone produces, and in
combination with fluoxetine facilitates antidepressant-like effects in rats as measured in a
forced swim test (Estrada-Camarena et al., 2006a; Estrada-Camarena et al., 2006b).
Furthermore, these affects are dependent on serotonin 1A (5-HT1A) receptors as a 5-HT1A
receptor antagonist blocked the antidepressant-like effects.
Desensitization of 5-HT1A receptor signaling in both midbrain and forebrain regions
(hypothalamus, amygdala, frontal cortex) may be an underlying mechanism for the
therapeutic effects of estrogen and of SSRIs such as fluoxetine for mood disorders and hot
flushes in peri- and post-menopausal women (Bosker et al., 2001; Gomez-Gil et al., 2010;
Navines et al., 2007; Nikisch et al., 2005; Shen et al., 2002). However, unlike SSRIs, which
require 7–14 days to induce desensitization of 5-HT1A receptor signaling and begin to
induce a therapeutic response, estrogens can produce a partial desensitization of 5-HT1A
receptor signaling within 2 days of administration in rodent models (Li et al., 1997; Li et al.,
1996; Mize and Alper, 2000; Mize et al., 2001; Raap et al., 2000; Uphouse et al., 1994). In
particular, two days of treatment with 17β-estradiol-3-benzoate (EB) results in partial
desensitization of 5-HT1A receptor signaling in the rat paraventricular nucleus of the
hypothalamus (PVN) (D’Souza et al., 2004; Raap et al., 2000). Stimulation of 5-HT1A
receptors in the PVN by the 5-HT1A/7 agonist (+)8-hydroxy-2-dipropylaminotetralin ((+)8-
OH-DPAT), stimulates the release of oxytocin and adrenocorticotropic (ACTH) hormones
(Osei-Owusu et al., 2003). Furthermore, the (+)8-OH-DPAT stimulated release of oxytocin
and ACTH is mediated by 5-HT1A receptors as demonstrated by inhibition with the selective
5-HT1A receptor antagonist WAY-100635 (Vicentic et al., 1998). Plasma oxytocin and
ACTH levels thus serve as markers for 5-HT1A receptor function in the PVN (Lerer et al.,
1999). In the PVN, 5-HT1A receptors couple to the Gαz subunit to mediate oxytocin and
ACTH hormone release (Serres et al., 2000). Gαz signaling is modulated by regulator of G-
protein signaling protein Z1 (RGSZ1), a GTPase-activating protein with approximately 20-
fold selectivity for Gαz over other members of the Gαi/o family (Glick et al., 1998). RGSZ1
accelerates hydrolysis of Gαz signaling over 400-fold, quickly blunting further downstream
signaling (Wang et al., 1998). Treatment with EB for two days increases the levels of a 30
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kD RGSZ1 protein in the membrane of the PVN in a dose-dependent manner without
affecting Gαz levels (Carrasco et al., 2004; Raap et al., 2000).
In the present study, we examined the dose-response and time course of the effects of EB
treatment on desensitization of 5-HT1A receptor signaling in the PVN. We further explored
possible mechanisms underlying the desensitization of 5-HT1A receptor signaling by
examining the expression of Gαz and other RGSZ1 isoforms as well as their interaction
following treatment with EB for 2 days. For comparison, we also examined the effects of
acute stimulation with the 5-HT1A receptor agonist (+)8-OH-DPAT on RGSZ1, Gαz and
their interaction. We examined expression of RGSZ1 and Gαz in several brain regions that
express 5-HT1A receptors and are associated with depression including the hypothalamus,
hippocampus and amygdala.
2. MATERIALS AND METHODS
2.1 Radioimmunoassays
Plasma oxytocin concentrations were determined by radioimmunoassay as previously
described (Rossi et al., 2010). Briefly, 1 ml of cold acetone followed by 2.5 ml petroleum
ether was used to extract oxytocin from 0.5 ml of plasma. The samples were dried in a
Centrivap vacuum concentrator at 4°C after the top ether layer was removed. The dried
residue was resuspended in 1 ml of cold assay buffer containing 0.05 M phosphate buffer
pH 7.4, 0.125% bovine serum albumin and 1.0 mM EDTA. The plasma extract was used for
the radioimmunoassay using radioactive 125I oxytocin (specific activity: 2200 Ci/mmol;
PerkinElmer; Waltham, MA). Plasma ACTH concentrations were determined as previously
described (Li et al., 1993).
2.2 Tissue preparation
The PVN, the rest of the hypothalamus, the dorsal hippocampus and amygdala brain regions
were punched out of 300 μm brain slices sectioned on a cryostat. The PVN was collected
from brain sections at the level of about −1.80 to ~ −2.7 mm from bregma. The rest of
hypothalamus was collected at the level of −1.80 to ~ −3.3 mm from bregma, and the
amygdala and dorsal hippocampus were collected from the sections at −2.4 to ~ −4.5 mm of
bregma based on co-ordinates from a rat brain atlas (Paxinos and Watson, 2007). Tissue was
stored at −80°C until use. The tissue was homogenized in 10 volumes (volume/tissue
weight) in homogenate buffer (50mM Tris, pH 7.4 containing 150mM NaCl, 10% sucrose,
20mM N-ethymaleimide isopeptidase inhibitor, 1X protease inhibitor cocktail (Sigma; St.
Louis, MO) and 1X phosphatase inhibitor cocktail I and II (Sigma; St. Louis, MO), using the
Powergene 1000 homogenizer (Fisher-Scientific; Waltham, MA) with a 5mm probe at speed
5 for 10 seconds on ice. The homogenates were then centrifuged at 25,000 × g at 4°C for 60
minutes. The supernatant was collected as the cytosol fraction. The pellet was then sonicated
at setting 3 for 5 seconds, at 4°C in 3 volumes of solubilization buffer containing 20mM
Tris, pH 8, 1mM EDTA, 100mM NaCl, 1% sodium cholate, 20mM N-ethymaleimide, 1X
protease inhibitor cocktail and 1X phosphatase inhibitor cocktails I and II. Vials were
shaken horizontally at 4°C for 60 minutes, centrifuged at 25,000 × g at 4°C for 1 hour and
the supernatant was collected as the membrane fraction. The cytosol and membrane
fractions were aliquoted and stored at −80°C. The protein concentration in these brain tissue
fractions was determined with the Pierce BCA protein assay using bovine serum albumin as
a standard (Thermo Fisher Scientific, Rockford, IL).
2.3 Immunoblot Analysis
RGSZ1 and Gαz protein levels in the membrane and cytosol fractions of the PVN, the rest
of the hypothalamus, amygdala and hippocampus were determined by immunoblot analysis.
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Briefly, after adding 4X sample buffer (350 mM Tris pH 6.8, 0.1% SDS, 45% glycerol,
0.001% bromophenol blue), samples were denatured at 95°C for 5 minutes then cooled on
ice. Since the RGSZ1 antibody reacts with the reducing agents DTT and β-mercaptoethanol,
the reducing agents were excluded from sample buffer. The samples (containing 10 μg of
protein) were resolved on 12% SDS-PAGE gels (acrylamide: bis-acrylamide = 30: 0.2), then
proteins were transferred to PVDF membranes. Non-specific binding was blocked by
incubating the membrane in 5% milk in TBST (50 mM Tris, pH 7.4 containing 150 mM
NaCl and 0.1% Tween 20). The blots were next incubated with rabbit-anti-RGSZ1 (1:2000)
or rabbit-anti-Gαz (Santa Cruz; Santa Cruz, CA, 1:2000) in TBST containing 2% milk
overnight at 4°C. After washing with TBST and incubation with goat-anti rabbit IgG
(1:10,000, Jackson Lab), the bands were then detected using ECL substrate solution (GE
Healthcare Biosciences, Piscataway, NJ) and captured using a BioRad ChemiDoc XRS+
molecular imager (BioRad, Hercules, CA). To normalize protein loading, the blots were
then incubated with β-actin antibodies (1:20,000, MP Biomedicals, Solon, OH). The
integrated optical density (IOD) of protein bands were analyzed densitometrically using
ImageLab software (BioRad, Hercules, CA). All samples were run in triplicate. RGSZ1 and
Gαz protein levels were normalized to β-actin protein levels and calculated as percent of the
mean of the vehicle-treated control group in each blot.
2.4 Co-immunoprecipitation
To determine the interaction between Gαz protein and RGSZ1, we immunoprecipitated
proteins binding to Gαz protein and then examined the proteins on immunoblots using an
antibody against RGSZ1. The membrane and cytosol fractions of the hypothalamus (without
the PVN) containing 200 μg of protein were incubated with 25 μl pre-washed protein G
agarose beads (Invitrogen Carlsbad, CA) in total volume of 500 μl of IP buffer (50mM Tris,
pH 7.4, 10mM EGTA, 100mM NaCl, 0.5% Triton X-100, 20mM N-ethymaleimide, 1X
protease inhibitor cocktail and 1X phosphatase inhibitor cocktail I and II) with rotation at
4°C for one hour to absorb the endogenous IgG. After centrifugation at 3,000 × g at 4°C for
5 minutes, the supernatant was incubated with 4 μg Gαz primary antibody (Santa Cruz;
Santa Cruz, CA) or 4 μg of rabbit IgG and rotated at 4°C overnight. A negative control
containing antibody but no tissue was also included in some assays. 50 μl of prewashed
protein G beads were added to each tube and rotated at 4°C for 2 hours. Protein G beads
were pelleted by centrifugation at 1,000 × g, at 4°C for 3 minutes and then resuspended in
0.5 mL ice cold IP buffer. After washing 3 times, the Gáz bound protein complexes were
eluted in 25 μl 2X sample buffer without β-mercaptoethanol by heating at 95°C for 5
minutes, then centrifuging at 3,000 rpm for 5 minutes. The supernatant was collected and
stored at −80°C.
Immunoprecipitated samples and 10 μg of original sample (input) were resolved on 12%
SDS-PAGE gels and transferred on PVDF membrane as described above. The membranes
were then incubated with rabbit-antiRGSZ1 antibody (1:2000) overnight at 4°C. An HRP-
conjugated secondary antibody that only recognizes intact IgG (Cleanblot, 1:1000, Thermo
Scientific, Rockford, IL) was used to reduce background from the rabbit antibody (anti-Gαz)
used for immunoprecipitation. Proteins were visualized by enhanced chemi-luminescence
detection (SuperSignal West Dura, Thermo Scientific, Rockford, IL). Membranes were then
incubated with Gαz primary antibody (Invitrogen; Carlsbad, CA, 1:2000) to be used as a
protein loading control. Each blot contained at least 3 samples from each treatment group
i.e., samples from EB, 8-OH-DPAT and vehicle-treated rats. Gαz-bound RGSZ1 protein
levels for each sample were first normalized to the Gαz protein level as a loading control
and then the samples in the EB and 8-OH-DPAT treatment groups were compared to the
vehicle-treated samples on that blot. Each sample was run in triplicate and the mean of the
normalized values for each sample was used for statistical comparisons.
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Hormone data were analyzed using 2- or 3-way ANOVA followed by Newman Keuls post-
hoc tests. The protein levels were analyzed by comparing the vehicle and 8-OH-DPAT
treated groups or the vehicle and EB treated groups using 1-way ANOVA via the Statview®
statistical software package.
3. EXPERIMENTAL PROCEDURES
Female Sprague-Dawley rats (200–225g) were purchased from Harlan Laboratories
(Indianapolis, IN). Animals were housed two per cage in a temperature-, humidity-, and
light- controlled room (12 hr light/dark cycle). Food and water were available ad libitum.
All procedures were conducted in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and as approved by the Loyola University
School of Medicine Institutional Animal Care and Use Committee. All efforts were made to
minimize animal suffering, to reduce the number of animals used, and to utilize available
alternatives to in vivo techniques. Rats were ovariectomized and given 5 days to recover
before drug treatments were initiated.
Two 17β-estradiol-3-benzoate (EB) dose-response experiments were performed, one in a
low dose range and a second experiment in a higher dose range of EB. In the low dose EB
dose-response experiment, rats were treated with 0.2, 2.0 or 10 μg/kg/day EB or the sesame
oil vehicle s.c. for 2 days. In the high dose EB dose-response experiment, rats were treated
with 10, 40 or 80 μg/kg/day EB or the sesame oil vehicle s.c. for 2 days. The next day, a
challenge injection of (+)8-OH-DPAT (40 or 200 μg/kg) or saline (0.9%) was given s.c. and
15 minutes later rats were sacrificed by decapitation. Trunk blood was collected and stored
at −80°C.
A time course experiment was performed to determine whether a single dose of EB would
result in changes in the hormone response to (+)8-OH-DPAT. Rats were treated with 10 μg/
kg EB s.c. 1, 2, 4, or 24 hours before a challenge dose of 200 μg/kg (+)8-OH-DPAT or
saline (0.9%) s.c. and rats were decapitated 5 minutes later. Trunk blood was collected and
stored at −80°C.
In the last experiment, each rat received daily injections of EB (10 μg/kg) or vehicle (sesame
oil) s.c. for 2 days. On the third day, a challenge injection of 200 μg/kg (+)8-OH-DPAT or
saline (0.9%) was given s.c. and 15 minutes later rats were sacrificed by decapitation. Trunk
blood was collected and stored at −80°C. Brains were removed and stored at −80°C.
4. RESULTS
4.1 Hormone Response to 8-OH-DPAT
Dose-response experiments were conducted to determine the dose of EB that would result in
maximal effects on 5-HT1A receptor signaling in the PVN. In the low dose dose-response
experiment, rats were treated with 0.2, 2.0 or 10 μg/kg/day of EB or vehicle for two days
and then challenged with 40 or 200 μg/kg 8-OH-DPAT or vehicle. Basal concentrations of
oxytocin were not significantly affected by any of the doses of EB (Figure 1A). Although 40
μg/kg (+)8-OH-DPAT did not significantly alter plasma oxytocin concentrations,
administration of 200 μg/kg of(+)8-OH-DPAT significantly increased plasma oxytocin
levels in all of the treatment groups. Treatment with 2.0 or 10 μg/kg/day of EB for 2 days
significantly reduced the plasma oxytocin levels in rats challenged with 200 μg/kg (+)8-OH-
DPAT compared to rats treated with oil for 2 days. Two-way ANOVA for plasma oxytocin
indicated a significant effect of EB (F(3,81) = 2.93, p < 0.05), a significant effect of (+)8-OH-
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DPAT (F(2,81) = 166.4, p < 0.0001) and a significant interaction between EB and (+)8-OH-
DPAT (F(6,81) = 3.7, p < 0.005).
In the high dose-dose-response experiment, rats were treated with 10, 40 or 80 μg/kg/day of
EB or vehicle for two days and then challenged with 40 or 200 μg/kg (+)8-OH-DPAT or
vehicle. Treatment with EB did not significantly change the baseline levels of oxytocin
(Figure 1B). The challenge injection of 200 μg/kg (+)8-OH-DPAT significantly increased
the levels of oxytocin in the plasma. Injection of 40 μg/kg 8-OH-DPAT significantly
increased the levels of oxytocin in the oil and 80 μg/kg EB treatment groups but not the
groups of rats treated with 10 or 40 μg/kg EB. Treatment with either 10, 40 or 80 μg/kg/day
of EB significantly reduced the increase in plasma oxytocin levels in response to 200 μg/kg
(+)8-OH-DPAT by approximately 40% compared to vehicle control. Two-way ANOVA
demonstrated a significant main effect of EB (F(3,71) = 7.81, p = 0.001), and (+)8-OH-DPAT
(F(2,71) = 171.8, p < 0.001), and a significant interaction between EB and (+)8-OH-DPAT
(F(6,71) = 4.73, p < 0.005).
In the time course experiment, rats were treated with a single injection of 10 μg/kg of EB or
oil and then given a challenge injection of 200 μg/kg (+)8-OH-DPAT or saline 1, 2, 4, or 24
hours later. EB did not significantly alter the baseline levels of oxytocin at any of the time
points examined (Figure 1C). Administration of 200 μg/kg of (+)8-OH-DPAT significantly
increased plasma oxytocin levels in all of the treatment groups. A single injection of 10 μg/
kg of EB at any of the time points examined did not significantly change the increase in
plasma oxytocin levels in response to the challenge injection of (+)8-OH-DPAT. A three-
way ANOVA demonstrated a significant main effect of the (+)8-OH-DPAT injection
(F(1,113) = 595.8, p < 0.001), but no significant effects of EB (F(1,113) = 2.67, p = 0.10), or
time (F(1,113) = 0.151, p = 0.93). There were also no significant interaction effects.
To verify the effect of 10 μg/kg/day of EB treatment for 2 days on 5-HT1A receptor function
in the rats used to examine the effects of EB on Gαz and RGSZ1 protein levels and
interaction, 10 μg/kg/day of EB or vehicle was given for two days and 18 hours after the last
dose rats were challenged with 200 μg/kg (+)8-OH-DPAT or vehicle. Basal oxytocin levels
did not differ between animals treated with vehicle and EB (Figure 1D). Administration of
200 μg/kg (+)8-OH-DPAT significantly increased plasma oxytocin levels 21-fold over
baseline. EB treatment significantly diminished the increase in plasma oxytocin induced by
(+)8-OH-DPAT. The two-way ANOVA for plasma oxytocin indicated a significant effect of
(+)8-OH-DPAT (F(1,28) = 231, p < 0.0001), a significant effect of EB (F(1,28) = 8.10, p <
0.01) and a significant interaction between (+)8-OH-DPAT and EB (F(1,28) = 8.02, p =
0.01).
4.2 Effect of (+)8-OH-DPAT and EB on Gαz and RGSZ1 Protein Levels
Western blot analysis was used to examine the effects of EB and 8-OH-DPAT on Gαz and
RGSZ1 protein levels in the PVN, hypothalamus without PVN, hippocampus and amygdala.
After separation of the proteins, the proteins were transferred to PVDF membranes. The
PVDF membranes were first examined with an antibody for Gαz and then were washed and
re-probed using an antibody directed against RGSZ1. The membrane and cytosol fractions
of these brain regions were analyzed separately on western blots. In membrane and cytosol
fractions, a 35 kD Gαz protein and a 40 kD RGSZ1 protein band were analyzed. In the
membrane fractions, a 55 kD RGSZ1 protein band was also measured; this band was present
in the membrane fraction but rarely detectable in the cytosol fractions of these brain regions.
Other RGSZ1 protein bands were detectable in these brain regions of rats in preliminary
experiments on untreated rats. However, RGSZ1 protein bands such as the 45 kD band
overlapped bands detected by the Gαz protein antibody which was used prior to the RGSZ1
antibody on the western blots prepared with tissue from EB- and (+)8-OH-DPAT-treated
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rats. The limited amount of tissue samples from these brain regions did not permit analysis
of RGSZ1 and Gαz protein on separate western blots.
Two days of EB did not change Gαz levels in either the membrane or cytosol fractions of
the hypothalamus, the hippocampus, and the amygdala or the membrane fraction of the PVN
(Figure 2). However, EB treatment resulted in a significant decrease in Gαz protein levels in
the cytosolic fraction of the PVN (F(1,13) = 9.78, p < 0.05).
Acute (+)8-OH-DPAT treatment significantly decreased Gαz protein levels in the cytosol
fraction of the PVN (F(1,13) = 6.53, p < 0.05) and the membrane fraction of the hippocampus
(F=5.68, p < 0.05) but did not significantly alter Gαz protein levels in the membrane or
cytosol fraction of the hypothalamus and the amygdale, the membrane fraction of the PVN
or the cytosol fraction of the hippocampus (Figure 2).
EB treatment resulted in a significant increase in the 55 kD RGSZ1 protein levels (Figure 3)
in the membrane fraction of the hypothalamus (F(1,15) = 38.88, p < 0.001); hippocampus
(F(1,13)= 11.75, p < 0.01), PVN (F(1,9) = 15.11, p < 0.01) and amygdala (F(1,14) = 14.25, p <
0.01). (+)8-OH-DPAT treatment also resulted in a significant increase in the 55 kD RGSZ1
protein levels in the membrane fraction of the hypothalamus (F(1,14) = 10.00, p < 0.01),
hippocampus (F(1,12) = 5.06, p < 0.05), PVN (F(1,7) = 5.86, p < 0.05) and the amygdala
(F(1,13) = 5.75, p < 0.05).
EB significantly increased the levels of the 40 kD RGSZ1 protein (Figure 4) only in the
membrane fraction of the hypothalamus (F(1,15) = 10.58, p < 0.01). In contrast EB caused a
significant decrease the levels of the 40 kD RGSZ1 protein in the membrane fraction of the
hippocampus (F(1,13) = 5.78, p < 0.05) and the PVN (F(1,14) = 8.90, p < 0.01) and the cytosol
fraction of the PVN (F(1,13) = 5.24, p < 0.05)
Acute (+)8-OH-DPAT treatment resulted in a significant increase in 40 kD RGSZ1 protein
levels (Figure 4) in the membrane fraction of the hypothalamus (F(1,15)=14.13, p < 0.01) but
a significant decrease in the membrane fraction of the PVN (F(1,14) = 7.90, p < 0.05) and the
membrane fraction of the amygdala (F(1,12) = 5.24, p < 0.05)
4.3 Co-immunoprecipitation
To examine the interaction of Gαz and RGSZ1, co-immunoprecipitation of Gαz and RGSZ1
was performed. To determine the linearity of the co-immunoprecipitation, five different
starting protein amounts from 100 μg to 500 μg were used, as well as an antibody control
without tissue homogenate. Gαz protein was immunoprecipitated from the membrane
fraction of the frontal cortex and the proteins were examined on western blots using an
RGSZ1 antibody. Two bands at 55 kD and 45 kD were detected on the western blots as well
as a large dark area above 75 kD (Figure 5A). In a control sample, immunoprecipitation was
performed without tissue homogenate, i.e., with only the Gαz antibody present. In this
control sample, the large dark area above 75kD and a 55 kD band were detectable and
assumed to be IgG protein from the Gαz antibody. Since the 55 kD IgG band obscures the
ability to independently detect the 55 kD RGSZ1 protein band (Figure 5A), only the 45 kD
band was analyzed in the co-immunoprecipitation assays. Immunoprecipitation of RGSZ1
with Gαz protein resulted in increases in the density of the RGSZ1 protein band with
increasing amounts of starting protein in the samples from 100 μg to 400 μg of homogenate
protein, however the assay reached a plateau with 500 μg of starting protein (Figure 5A).
Since 200 μg of protein in the tissue homogenates are sufficient to co-immunoprecipitate
Gαz and RGSZ1, 200 μg of protein was used in all further immunoprecipitation assays. To
further verify the immunoprecipitation of Gαz protein and co-immunoprecipitation of
RGSZ1, a control experiment was performed using the membrane fraction of the
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hippocampus (Figure 5B). After immunoprecipitation of Gαz protein, the proteins were
examined on a western blot with the RGSZ1 antibody (Figure 5B right) and an antibody
against Gαz (Figure 5B left).
4.4 Gαz and RGSZ1 interaction in the hypothalamus
Co-immunoprecipitation of Gαz and RGSZ1 was evaluated in both the membrane and
cytosol fractions of the hypothalamus (excluding the PVN) after daily injections of EB for 2
days, acute (+)8-OH-DPAT injection or vehicle treatments (Fig. 5C). EB treatment caused a
significant decrease in co-immunoprecipitation of Gαz and RGSZ1 in the membrane
fraction of the hypothalamus (F(1,10) = 11.60, p < 0.01) and a significant increase in co-
immunoprecipitation in the cytosol fraction of the hypothalamus (F(1,14) = 21.91, p < 0.001).
Similarly, acute (+)8-OH-DPAT treatment significantly decreased co-immunoprecipitation
of Gαz and RGSZ1 in the membrane (F(1,9) = 8.38, p < 0.05), but significantly increased in
the cytosol (F(1,14) = 7.83, p < 0.05) of the hypothalamus.
5. DISCUSSION
Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is characteristic of
depressed patients. Normalization of HPA axis responses coincides with clinical
responsiveness to antidepressant medications including SSRIs such as fluoxetine and
citalopram, and the non-selective tricyclic antidepressant imipramine (Gomez-Gil et al.,
2010; Navines et al., 2007; Nikisch et al., 2005). For example, hormone responses to a
challenge with the 5-HT1A receptor agonists buspirone or ipsapirone are reduced after
chronic treatment with antidepressant therapy in clinical studies (Gomez-Gil et al., 2010;
Lerer et al., 1999; Navines et al., 2007; Nikisch et al., 2005). This diminished
responsiveness in the hormone response to a challenge dose of a 5-HT1A receptor agonist
indicates that desensitization of 5-HT1A receptor signaling in the PVN can play an important
role in the clinical response to antidepressant therapy. These clinical responses in human
trials can be modeled in rodents. Treatment of rats with SSRIs for 7 to 14 days results in
desensitization of the hormone responses to a challenge dose of a 5-HT1A receptor agonist
(Li et al., 1997; Li et al., 1996) suggesting that this rat model can be used to examine other
potential therapeutic approaches for depression as well as possible adjuvant therapies such
as estrogens to reduce the response time to antidepressant treatments.
Our previous studies demonstrated that a partial desensitization of the oxytocin and ACTH
responses to 5-HT1A receptor stimulation could be produced by two once daily injections of
EB at doses of 2 μg/kg (Rossi et al., 2010), 10 μg/kg (Xu et al., 2009) and 10 μg/rat i.e.,
approximately 42 μg/kg (Raap et al., 2000). However, a direct comparison of the EB dose
and the desensitization response had not been established. In the current study, we
performed two dose response experiments, one using low doses of EB (0.2 – 10 μg/kg) and
the other using higher doses (10 – 80 μg/kg). The results from these experiments
demonstrate that EB is only capable of producing a partial desensitization of the oxytocin
response to 5-HT1A receptor stimulation and this response reaches a maximum of
approximately a 40% reduction at the 10 μg/kg dose. Further increases in the dose of EB did
not result in further reductions in the plasma oxytocin concentrations induced by 5-HT1A
receptor stimulation. These experiments also demonstrated that 2.0 μg/kg/day EB for 2 days
resulted in a lower 25% reduction in the plasma concentrations of oxytocin induced by 5-
HT1A receptor stimulation but 0.2 μg/kg EB had no significant effects on plasma oxytocin
concentrations.
Although the data clearly demonstrate that two days of administration of EB is sufficient to
produce a partial desensitization of the oxytocin response to 5-HT1A receptor stimulation,
we did not know whether a single dose of EB was capable of producing desensitization. To
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address this question, we performed a time course experiment to determine whether a single
dose of 10 μg/kg EB would produce desensitization of 5-HT1A receptor signaling in the
PVN. A single dose of EB, examined from 1 to 24 hours after administration, did not
significantly reduce the oxytocin response to 5-HT1A receptor stimulation. From this
experiment, we can conclude that at least 2 days of administration of 10 μg/kg EB are
necessary for desensitization of the oxytocin response to 5-HT1A receptor stimulation.
However, it is also possible that a single higher dose of EB could produce desensitization of
5-HT1A receptor signaling after 24 hours and that a single dose of 10 μg/kg EB could
produce a desensitization response after 48 hours.
The mechanisms underlying the EB-induced desensitization of 5-HT1A receptor signaling
are beginning to be elucidated. Several studies have focused on identifying the estrogen
receptor mediating the EB-induced desensitization of 5-HT1A receptor signaling in the PVN
(Rossi et al., 2010; Xu et al., 2009). The results from these studies suggest that the G protein
coupled estrogen receptor GPR30 (also known as GPER) but not estrogen receptor β in the
PVN is necessary for EB-induced desensitization of 5-HT1A receptor signaling. Further
studies are needed to determine if there is a role for estrogen receptor a in the desensitization
of 5-HT1A receptor signaling in the PVN.
The impact of EB on components of the 5-HT1A receptor system in the PVN has been
previously examined and was further examined in the current study. Previous studies
demonstrated an increase in the expression of a 30kD RGSZ1 protein in the membrane
fraction of the PVN (Carrasco et al., 2004) However, there was no change in the levels of
Gαz in the membrane fraction of the PVN (D’Souza et al., 2004). Similar to our findings in
the previous study, there was no change in the expression of Gαz in the membrane fraction
of the PVN in the present study. However, in the current study, we also examined the
cytosol fraction of the PVN and now found that the expression of Gαz was decreased by EB
treatment. In the present study, we examine the effects of EB on two RGSZ1 isoforms, a
40kD and a 55kD protein. EB reduced the 40kD RGSZ1 protein in both the membrane and
cytosol fraction of the PVN by approximately 20% but increased the 55kD RGSZ1 protein
in the membrane fraction to over 250% of control values for a net increase in the expression
of these RGSZ1 proteins in the membrane of the PVN. This increase in RGSZ1 in the
membrane of the PVN could play a role in the desensitization response via the GTPase
accelerating protein (GAP) function of RGS proteins.
The RGS20 gene encodes both RGSZ1 and Ret RGS (Barker et al., 2001). Multiple start
sites for transcription of RGSZ1 likely contribute to the heterogeneity in protein size in the
lower molecular weight range (Barker et al., 2001) and could account for the multiple
protein bands between 25 and 30 kD identified in rat brain tissue on western blots. RGSZ1
undergoes multiple posttranslational modifications including N- and O-linked glycosylation
(Garzon et al., 2004), sumoylation by sumo1 and sumo2 and serine phosphorylation
(Rodriguez-Munoz et al., 2007) which contribute to the presence of multiple higher
molecular weight bands detected on western blots. RGSZ1 contains a cysteine string region
which is a likely region for palmitoylation and regulation of membrane association (Barker
et al., 2001; De Vries et al., 1996). The post-translational modifications resulting in the
40kD and 55kD RGSZ1 protein bands are unknown but since the 55kD band predominantly
exists in the membrane fraction, modifications to the 55kD band are likely to include those
that increase hydrophobicity and thereby membrane association such as palmitoylation.
Further studies are needed to determine alternative mRNA splicing, post-translational
modifications, dimer or polymer formation and the functional differences among these
isoforms of RGSZ1.
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Acute (+)8-OH-DPAT treatment resulted in a similar pattern of changes in the expression of
Gαz and RGSZ1 in the PVN, though several of the changes that resulted from EB treatment
did not reach significance with (+)8-OH-DPAT treatment. The most striking effect of (+)8-
OH-DPAT was an over 350% increase in the 55kD RGSZ1 protein which could contribute
to a possible tachypylaxis response in the 5-HT1A receptor signaling system.
In the other brain regions examined, the 55kD RGSZ1 protein also increased with EB or
(+)8-OH-DPAT treatment; the magnitude of the increases were large in the rest of the
hypothalamus, similar to the PVN but were much more modest in the hippocampus and
amygdala. In the rest of the hypothalamus, hippocampus and amygdala, there were no
effects of either EB or (+)8-OH-DPAT on Gαz protein and there were region specific
changes in the expression of the 40kD RGSZ1 protein.
We examined the binding of RGSZ1 to Gαz following treatment with either EB or (+)8-OH-
DPAT in the hypothalamus (without the PVN). Both treatments resulted in decreased
binding in the membrane fraction and increased binding in the cytosol fraction of the
hypothalamus. RGSZ proteins bind to active Gα proteins and transition state Gα proteins in
contrast to other RGS proteins which only bind to the transition state (Wang et al., 1997).
Binding of RGSZ1 to activated Gαz could act to sequester the activated Gαz from down-
stream effectors resulting in effector antagonism in the membrane fraction. The decreased
binding of RGSZ1 to Gαz in the membrane fraction of the hypothalamus could result in
increased responsiveness to 5-HT1A receptor stimulation. Although there is a rich literature
demonstrating the effects of RGSZ1 on opioid receptor signaling, the effects of 5-HT1A
receptor signaling (Ghavami et al., 2004) are not as well documented. Stimulation of mu
opioid receptors rapidly (within 45min) increases binding of RGSZ2 to Gαi2 in synaptic
membrane (Sanchez-Blazquez et al., 2010). Similarly, the sequestration of receptor activated
Gαz by RGSZ2 proteins was thought to contribute to desensitization of mu opioid receptors
(Garzon et al., 2005). Since there is both a decrease in the binding of RGSZ1 to Gαz which
could increase signaling and an large increase in the amount of the 55kD and 40 kD RGSZ1
in the membrane fraction after treatment with EB or (+)8-OH-DPAT, which could decrease
signaling, the net effect on 5-HT1A receptor- Gαz signaling in the hypothalamus (without
the PVN) is unclear.
5.1 Conclusions
The present study provided important information regarding the dose and time course of EB
administration that produces maximal effects on desensitization of 5-HT1A receptor
signaling in the PVN. Since normalization of HPA axis responses especially to 5-HT1A
receptor stimulation coincides with anti-depressive responses clinically, a brief initial
adjuvant treatment with EB in combination with SSRIs has the potential to induce a more
rapid clinical response especially for the treatment of post-menopausal depression and
should be tested in this rat model. Estrogen clearly plays an important role in depression and
the treatment of depression. Understanding the mechanisms underlying the more rapid
estrogen-dependent desensitization of 5-HT1A receptor signaling in the PVN may also lead
to the identification of novel targets for the treatment of depression. The additional changes
in RGSZ1 protein with EB treatment identified in the current study further strengthen the
importance of this protein as a target for the treatment of depression. Further studies are
needed to clarify the role of RGSZ1 protein isoforms in 5-HT1A receptor signaling and their
involvement in the mechanisms by which estrogen impacts on receptor systems mediating
depression and anti-depressive responses.
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2 once daily doses of EB is the minimum to induce desensitization of 5-HT1A
receptors
10 μg/kg/day EB produces the Emax response partial desensitization of 5-HT1A
receptors
EB greatly increased a 55 kD membrane-associate RGSZ1 protein in hypothalamus
EB increased a 55 kD membrane-associate RGSZ1 protein in amygdala &
hippocampus
EB is a candidate for adjuvant therapy with SSRIs to hasten the therapeutic response
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Oxytocin responses to (+)8-OH-DPAT stimulation following treatment with EB. A) Results
from a low dose dose-response experiment demonstrate that 2.0 and 10.0 μg/kg/day EB, but
not 0.2 μg/kg/day EB, causes desensitization of the oxytocin response to stimulation of 5-
HT1A receptors. B) Results from the high dose dose-response experiment demonstrate that
10.0, 40 and 80 μg/kg/day EB for two days cause similar levels of partial desensitization of
the oxytocin response to stimulation of 5-HT1A receptors. Treatment with 10.0 μg/kg/day
EB for 2 days causes the maximal desensitization response; further increases in the dose of
EB above 10.0 μg/kg/day do not induce further decreases in the oxytocin response to 5-
HT1A receptor stimulation. C) Results from the time course experiment demonstrate that 1,
2, 4 or 24 hours after a single injection of EB the oxytocin response to stimulation of 5-
HT1A receptors is not altered. D) We verified the desensitization of 5-HT1A receptor
signaling after treatment with 10.0 μg/kg/day EB for two days in the rats used for the
western blot and co-immunoprecipiatation assays by measuring the plasma oxytocin
concentrations after challenge with either (+)8-OH-DPAT or vehicle control. The * indicates
significantly different from the saline-challenged group receiving the same pre-treatment at
p < 0.05, # indicates significantly different from the group treated with oil and challenged
with (+)8-OH-DPAT at p < 0.05.
Creech et al. Page 15














Representative images and quantitation of the Gαz protein examined on western blots. Gαz
protein levels were examined in the membrane and cytosol fractions of the PVN(A), rest of
the hypothalamus(B), hippocampus(C) and amygdala(D) after treatment with 10.0 μg/kg/
day EB for 2 days, 15 minutes after 200 μg/kg (+)8-OH-DPAT, or vehicle. EB and (+)8-
OH-DPAT caused a reduction in Gαz protein in the cytosol fraction of the PVN and in the
membrane fraction of the hippocampus. The * indicates significantly different from the
saline-treated group at p < 0.05.
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Representative images and quantitation of the 55 kD RGSZ1 protein examined on western
blots. The 55 kD RGSZ1 protein was measured in the membrane fraction of the PVN(A),
rest of the hypothalamus(B), hippocampus(C) and amygdala(D) after treatment with 10.0
μg/kg/day EB for 2 days, 15 minutes after 200 μg/kg (+)8-OH-DPAT, or vehicle. Both EB
and (+)8-OH-DPAT increased the levels of the 55kD RGSZ1 protein compared to vehicle
controls in all of the brain regions examined. The * indicates significantly different from the
saline-treated group at p < 0.05.
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Representative images and quantitation of the 40 kD RGSZ1 protein examined on western
blots. The 40 kD RGSZ1 protein was examined in the membrane and cytosol fractions of the
PVN(A), rest of the hypothalamus(B), hippocampus(C) and amygdala(D) after treatment
with 10.0 μg/kg/day EB for 2 days, 15 minutes after 200 μg/kg (+)8-OH-DPAT, or vehicle.
Each brain region examined displayed a unique pattern of changes in the expression of the
40 kD RGSZ1 protein. The * indicates significantly different from the saline-treated group
at p < 0.05.
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Co-immunoprecipitation of RGSZ1 with Gαz protein. A) A concentration response
experiment was performed to determine the optimum amount of protein to use in the co-
immunoprecipitation assays and to determine the linearity of the assay. B) A control
experiment was performed to determine if RGSZ1 protein would co-immunoprecipitate with
the Gαz protein. Proteins were immunoprecipitated using an antibody directed against Gαz
protein (Rab-anti-Gαz) and western blots were performed using the RGSZ1 antibody (left,
Rab-anti-RGSZ1) and the Gαz antibody (right). C) Representative image and quantitation of
RGSZ1 protein co-immunoprecipitated with Gαz protein in the membrane and cytosol
fractions of the PVN after treatment with 10.0 μg/kg/day EB for 2 days, 15 minutes after
200μg/kg (+)8-OH-DPAT, or vehicle. EB and (+)8-OH-DPAT decreased the association of
RGSZ1 with Gαz protein in the membrane fraction and EB increased the association in the
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cytosol fraction of the PVN. The * indicates significantly different from the saline-treated
group at p < 0.05. MW marker indicates the lane loaded with molecular weight standard
markers, input indicates the lanes loaded with tissue homogenate not subjected to
immunoprecipitation, IgG indicates the lanes loaded with homogenate immunoprecipitated
with a non-specific rabbit IgG protein as a control.
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